WallStreetZenWallStreetZen

NASDAQ: ORIC
Oric Pharmaceuticals Inc Stock

$9.51-0.25 (-2.56%)
Updated Apr 18, 2024
ORIC Price
$9.51
Fair Value Price
$0.26
Market Cap
$640.74M
52 Week Low
$4.89
52 Week High
$16.65
P/E
-4.85x
P/B
2.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$86M
Beta
0.94
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ORIC Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORIC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORIC ($9.51) is overvalued by 3,614.96% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORIC ($9.51) is not significantly undervalued (3,614.96%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORIC due diligence checks available for Premium users.

Be the first to know about important ORIC news, forecast changes, insider trades & much more!

ORIC News

Valuation

ORIC fair value

Fair Value of ORIC stock based on Discounted Cash Flow (DCF)
Price
$9.51
Fair Value
$0.26
Overvalued by
3,614.96%
ORIC ($9.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORIC ($9.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ORIC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.85x
Industry
15.68x
Market
41.33x

ORIC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.86x
Industry
5.76x
ORIC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ORIC's financial health

Profit margin

Revenue
$0.0
Net Income
-$28.3M
Profit Margin
0%
ORIC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$252.0M
Liabilities
$27.9M
Debt to equity
0.13
ORIC's short-term assets ($212.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORIC's short-term assets ($212.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORIC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORIC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$24.3M
Investing
$21.0M
Financing
$453.0k
ORIC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ORIC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ORIC$640.74M-2.56%-4.85x2.86x
LBPH$648.67M+5.94%-7.54x15.85x
PHAR$626.11M-8.26%-53.62x2.63x
YMAB$656.66M-0.73%-30.61x6.50x
SVRA$661.73M-3.43%-14.52x4.71x

Oric Pharmaceuticals Stock FAQ

What is Oric Pharmaceuticals's quote symbol?

(NASDAQ: ORIC) Oric Pharmaceuticals trades on the NASDAQ under the ticker symbol ORIC. Oric Pharmaceuticals stock quotes can also be displayed as NASDAQ: ORIC.

If you're new to stock investing, here's how to buy Oric Pharmaceuticals stock.

What is the 52 week high and low for Oric Pharmaceuticals (NASDAQ: ORIC)?

(NASDAQ: ORIC) Oric Pharmaceuticals's 52-week high was $16.65, and its 52-week low was $4.89. It is currently -42.88% from its 52-week high and 94.48% from its 52-week low.

How much is Oric Pharmaceuticals stock worth today?

(NASDAQ: ORIC) Oric Pharmaceuticals currently has 67,375,847 outstanding shares. With Oric Pharmaceuticals stock trading at $9.51 per share, the total value of Oric Pharmaceuticals stock (market capitalization) is $640.74M.

Oric Pharmaceuticals stock was originally listed at a price of $25.77 in Apr 24, 2020. If you had invested in Oric Pharmaceuticals stock at $25.77, your return over the last 3 years would have been -63.1%, for an annualized return of -28.27% (not including any dividends or dividend reinvestments).

How much is Oric Pharmaceuticals's stock price per share?

(NASDAQ: ORIC) Oric Pharmaceuticals stock price per share is $9.51 today (as of Apr 18, 2024).

What is Oric Pharmaceuticals's Market Cap?

(NASDAQ: ORIC) Oric Pharmaceuticals's market cap is $640.74M, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oric Pharmaceuticals's market cap is calculated by multiplying ORIC's current stock price of $9.51 by ORIC's total outstanding shares of 67,375,847.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.